BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (AMEX: DDD) today announced that on June 28, 2007, the Company received notification from the American Stock Exchange (“AMEX”) that it is not in compliance with Sections 121(A)(1) and 802(a) of the AMEX Company Guide. Specifically, the AMEX letter states that the Company does not have a sufficient number of independent directors such that a majority of its board of directors is deemed to be “independent” as such defined in the AMEX Company Guide.
